Celerity Group

Cellarity is a Flagship Pioneering-founded biotechnology company that is re-architecting drug discovery by focusing on cell behavior rather than single molecular targets. The company's proprietary platform, which includes the Cellarium digital twin and Cellarity Maps, leverages single-cell transcriptomics and machine learning to identify and correct the network state of diseased cells. By digitizing biology and drug action, Cellarity aims to design medicines that can precisely regulate genetic switch mechanisms to restore proper cell function. The company's lead asset, CLY-124, is currently in Phase 1 clinical trials for the treatment of sickle cell disease, and it maintains a significant research collaboration with Novo Nordisk to develop novel therapies for metabolic dysfunction-associated steatohepatitis (MASH).